Zenas BioPharma Boosts Capital from Public Offering
WALTHAM, Mass. - Zenas BioPharma, Inc. (NASDAQ: ZBIO), an innovative clinical-stage biopharmaceutical company, has recently announced some great news regarding its public offering success. With a strong focus on transforming therapies in immunology, Zenas revealed that the underwriters of its previously upsized initial public offering have fully exercised their option to acquire additional shares.
Offering Details
Zenas initially planned to offer 13,235,294 shares of its common stock. However, the underwriters opted to purchase an extra 1,985,294 shares at the price of $17.00 each. Following this transaction, which was finalized on a recent date, Zenas managed to raise about $258.7 million by selling a total of 15,220,588 shares—all offered directly by the company. Since the offering began, Zenas has quickly established itself in the Nasdaq Global Select Market under the ticker symbol "ZBIO".
Market Participation and Oversight
Prominent investment firms, including Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities, acted as the joint book-running managers for this significant offering. Their involvement signals the market's confidence in Zenas BioPharma's promising potential and its groundbreaking contributions to medicine.
Regulatory Adherence
In line with regulatory requirements, Zenas filed registration statements concerning the shares sold with the U.S. Securities and Exchange Commission. These statements have recently become effective. Consistent with standard practices, the offering was marketed exclusively through a prospectus for complete regulatory compliance.
About Zenas BioPharma, Inc.
Zenas BioPharma is committed to patients dealing with autoimmune diseases. As a clinical-stage company, it aspires to lead the way in immunology therapies. Their flagship product candidate, obexelimab, embodies this innovative spirit. This bifunctional monoclonal antibody is uniquely designed to target both CD19 and Fc?RIIb, effectively inhibiting the activity of cells that drive many autoimmune disorders without depleting those cells.
Investor Relations Contact
If you have questions about investments or want to know more about the company's strategic direction, Matthew Osborne heads the Investor Relations and Corporate Communications at Zenas. You can reach him via email at Matt.osborne@zenasbio.com.
Media Relations Contact
For media inquiries, Argot Partners is the designated contact for Zenas BioPharma. You can get in touch with them at Zenas@argotpartners.com.
Frequently Asked Questions
What was the total amount raised in Zenas BioPharma's offering?
Zenas BioPharma raised around $258.7 million from selling 15,220,588 shares during its initial public offering.
When did Zenas BioPharma's shares start trading?
The shares of Zenas BioPharma began trading on the Nasdaq Global Select Market on a recent date, under the ticker symbol "ZBIO".
Who managed the public offering for Zenas BioPharma?
The public offering was managed by Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities.
What is Zenas BioPharma's lead product candidate?
The leading product candidate for Zenas BioPharma is obexelimab, which targets treatment for autoimmune diseases.
How can I contact Zenas BioPharma for investment inquiries?
Investors can reach out to Matthew Osborne at Zenas via the email address Matt.osborne@zenasbio.com.
